

DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES

ABSTRACT OF THE DISCLOSURE

The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.